1 |
P-glycoprotein
(8552 times)
|
Pharmacology (2479 times)
|
MDR (1968 times) BCRP (496 times) BBB (493 times)
|
1988 Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and Chinese hamster ovary multidrug-resistant cells.
|
2 |
permeability glycoprotein
(143 times)
|
Pharmacology (28 times)
|
mdr (25 times) BCRP (9 times) MRP1 (8 times)
|
1993 Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
|
3 |
anti-P-glycoprotein
(17 times)
|
Neoplasms (9 times)
|
MDR (5 times) MRP (4 times) ADCC (2 times)
|
1993 Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
|
4 |
phosphoglycoprotein
(17 times)
|
Neoplasms (5 times)
|
ABC (4 times) BCRP (3 times) MDR (3 times)
|
1997 Evaluation of P-glycoprotein expression in human oral oncogenesis: correlation with clinicopathological features.
|
5 |
glycoprotein P
(13 times)
|
Pharmacology (3 times)
|
MDR (6 times) PTX (3 times) 5-HT (1 time)
|
1995 Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line.
|
6 |
P-glycoprotein transporter
(6 times)
|
Neurology (1 time)
|
AEDs (1 time) BBB (1 time) CSF (1 time)
|
2007 In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites.
|
7 |
P-glycoprotein substrate
(4 times)
|
Pharmacology (3 times)
|
ALP (1 time) AUC (1 time) HIA (1 time)
|
2004 Loperamide modifies the tissue disposition kinetics of ivermectin in rats.
|
8 |
plasma membrane glycoprotein
(4 times)
|
Gynecology (2 times)
|
EGFR (2 times) HB-EGF (2 times) Rh123 (2 times)
|
1996 Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells.
|
9 |
P-glycoprotein multidrug transporter protein
(3 times)
|
Biology (3 times)
|
MXR (4 times)
|
2000 Induction of the multixenobiotic defense mechanism (MXR), P-glycoprotein, in the mussel Mytilus californianus as a general cellular response to environmental stresses.
|
10 |
protein Pglycoprotein
(3 times)
|
Drug Therapy (1 time)
|
BA (1 time) BBB (1 time) BMECs (1 time)
|
2015 [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].
|
11 |
P-glycoprotein expression
(2 times)
|
Hematology (1 time)
|
AML (1 time) MDR (1 time) MDS (1 time)
|
1991 Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype.
|
12 |
chemical-P-glycoprotein
(1 time)
|
Chemistry (1 time)
|
---
|
2013 Automated extraction of information on chemical-P-glycoprotein interactions from the literature.
|
13 |
DNA-PKcs/Akt/GSK-3beta signaling pathway, and higher inhibition of MDR1
(1 time)
|
Neoplasms (1 time)
|
TRAIL (1 time)
|
2015 [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
|
14 |
glycoprotein p-170
(1 time)
|
Endocrinology (1 time)
|
MDR (1 time) rMCF7 (1 time)
|
2007 Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
|
15 |
overexpressing glycoprotein-P
(1 time)
|
Biochemistry (1 time)
|
MDR (1 time)
|
2007 Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines.
|
16 |
P-glycation protein
(1 time)
|
Cell Transformation, Neoplastic (1 time)
|
AL (1 time) HMGB1 (1 time) MRP (1 time)
|
2021 Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute leukemia cells.
|
17 |
P-glycoprotein efflux pump
(1 time)
|
Chemistry (1 time)
|
GCPh (1 time)
|
2016 Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate.
|
18 |
P-glycoprotein inhibitor
(1 time)
|
Pharmaceutical Preparations (1 time)
|
ABL (1 time) VER (1 time)
|
2021 In Situ Absorption Study of Acebutolol by Modulating P-glycoprotein with Verapamil in Rats.
|
19 |
P-glycoprotein protein
(1 time)
|
Pharmaceutical Preparations (1 time)
|
CSCs (1 time) DAPI (1 time) MTT (1 time)
|
2022 Curcumin Upregulates miR-148a to Increase the Chemosensitivity of CD44-Positive Prostate Cancer Stem Cells to Paclitaxel Through Targeting the MSK1/IRS1 axis.
|
20 |
P-glycoprotein pump
(1 time)
|
Drug Therapy (1 time)
|
APTT (1 time) AUC (1 time) CYP450 (1 time)
|
2007 Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
|
21 |
P-glycoprotein-170
(1 time)
|
Drug Therapy (1 time)
|
MDR (1 time)
|
2002 P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.
|
22 |
P-type glycoproteins
(1 time)
|
Drug Therapy (1 time)
|
GI (1 time)
|
2012 Pharmaceutical nanotechnology for oral delivery of anticancer drugs.
|
23 |
permeability drug resistance glycoprotein
(1 time)
|
Neoplasms (1 time)
|
BC (1 time) PgR (1 time) SPF (1 time)
|
1995 Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers.
|
24 |
Permeation glycoprotein
(1 time)
|
|
---
|
2021 Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms.
|
25 |
pharmacophoric features responsible for the glycoprotein P
(1 time)
|
Crystallography (1 time)
|
---
|
2021 Crystallographic studies of piperazine derivatives of 3-methyl-5-spirofluorenehydantoin in search of structural features of P-gp inhibitors.
|
26 |
phenotype in LoVo/Adr cells through up-regulating expression of MDR-1
(1 time)
|
Neoplasms (1 time)
|
MDR (1 time)
|
2011 CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53.
|
27 |
phosphorylated glycoprotein
(1 time)
|
Pharmacology (1 time)
|
MDR (1 time) PCBs (1 time)
|
2003 Polychlorinated biphenyls are not substrates for the multidrug resistance transporter-1.
|
28 |
Pleotropic-glycoprotein
(1 time)
|
Internal Medicine (1 time)
|
CCNU (1 time) CR (1 time) DTIC (1 time)
|
2008 Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
|
29 |
polymorphism in genes encoding different drug metabolizing enzymes, drug transporters
(1 time)
|
Medicine (1 time)
|
---
|
2014 Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
|
30 |
Previous pharmacokinetic characterization of a transporter probe cocktail containing digoxin
(1 time)
|
Pharmacology (1 time)
|
DDI (1 time)
|
2018 Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
|
31 |
product, phosphoglycoprotein
(1 time)
|
Brain (1 time)
|
BBB (1 time) DEX (1 time) PTL (1 time)
|
2010 Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation.
|
32 |
pumps such as glycoprotein P
(1 time)
|
Drug Therapy (1 time)
|
DNM (1 time) MDR (1 time) MRP1 (1 time)
|
2005 Trimers of N-alkylglycines are potent modulators of the multidrug resistance phenotype.
|
33 |
transporter--P-glycoprotein
(1 time)
|
Genetics (1 time)
|
BPH (1 time) DAC (1 time) HGPIN (1 time)
|
2013 Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
|
34 |
transporters-permeability glycoprotein
(1 time)
|
Nuclear Medicine (1 time)
|
BCRP (1 time) cAMP (1 time) PDE4 (1 time)
|
2022 First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.
|